Mechanistically, sorafenib-related antiangiogenic therapy-induced hypoxia-activated HIF-1α/NF-κB signaling increases chemokine CXCL5 secretion in HCC cells, thereby recruiting TAN and inhibiting apoptosis. The gene discussed is NFKB1; the disease is hepatocellular carcinoma.